State-of-the-Art PaperMitochondria as a Therapeutic Target in Heart Failure
Key Words
Abbreviations and Acronyms
Cited by (0)
This work was supported, in part, by grants from the National Institutes of HealthK02 HL107448, R01 HL104181, and 1P01 HL108795 (to Dr. Ardehali). Dr. Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd., CorThera, Cytokinetics, CytoPherx, Inc., DebioPharm S.A., Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Intersection Medical, Inc., Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Pharmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, sanofi-aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America, Inc., and Trevena Therapeutics; and has received significant (>$10,000) support from Bayer Schering Pharma AG, DebioPharm S.A., Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, and Takeda Pharmaceuticals North America, Inc. Dr. Ardehali is a consultamt for Cubist Pharma, Novartis, and the Gerson Lehman Group, and is a speaker for Merck. Dr. Bayeva has reported that she has no relationships relevant to the contents of this paper to disclose.